These data support the hypothesis that CXCL12-LD promotes long-term mobilization of CXCR4-expressing cells into the peripheral blood and could be used to remove AML blasts out of the chemoprotective bone marrow niche. Here, CXCL12 is linked to acute myeloid leukemia.